PARIS (dpa-AFX) - Sanofi (SNYNF) on Monday said its Sarclisa in combination with carfilzomib, lenalidomide and dexamethasone (KRd) significantly improved rate of minimal residual disease (MRD) negativity in transplant-eligible patients with newly diagnosed multiple myeloma in late-stage study.
MRD negativity is defined as the absence of myeloma cells in the bone marrow after treatment, Sanofi said.
Results from the Phase 3 study showed that 77% patients with newly diagnosed, transplant-eligible multiple myeloma achieved MRD negativity when treated with Sarclisa plus KRd compared with KRd alone.
Copyright(c) 2023 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2023 AFX News
